Intellia Therapeutics Inc. and Recode Therapeutics Inc. have established a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis.

Attovia Therapeutics Inc. has announced the closing of the $30 million second tranche of its $60 million series A financing.

Anima Biotech Inc. has released promising preclinical data on its new candidate, which has potential for treating idiopathic pulmonary fibrosis (IPF).

Aatec Medical GmbH has announced the start of its collaboration with the German Federal Agency for Disruptive Innovations (SPRIND), which will help advance the preclinical development of ATL-105.

Burn injuries, including those induced by chemicals, may have systemic effects, and can lead to acute lung injury (ALI). Chemical burn injuries account for about 2% to 5% of total skin burn injuries. Among the chemicals, vesicating agents like Lewisite are particularly relevant due to the lack of antidotes.

A common molecular pathway associated with lung fibrosis may also hold the key to pulmonary vascular repair. A group of scientists at the University of Pennsylvania (Penn) found that when a viral infection damaged these vessels, the injury could be restored by activating the transforming growth factor-β receptor 2 (TGF-βR2) in endothelial cells, which led to cell proliferation.

Royal Philips NV agreed with the U.S. FDA to the terms of a consent decree focused on its Respironics business, following the recall of millions of its devices over the last few years. Although the details of the decree are being finalized, Philips said it will halt the sales of new continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) sleep therapy machines as well as other respiratory care devices in the U.S. until the conditions of the decree are met.